Biodesix Reports Strong Q1 2026 Performance with Revenue Growth and Strategic Expansion
Biodesix reported a revenue growth of 42% in Q1 2026, driven by increased diagnostic test volumes and development services. The company raised its full-year revenue guidance to $108 million to $114 million due to strong performance and improved demand visibility.
Topics: diagnostic_business gross_margin_improvement revenue_growth sales_expansion